

Abbott Laboratories (ABT)

\$128.54 (Stock Price as of 11/26/2025)

Price Target (6-12 Months): **\$138.00**

Long Term: 6-12 Months | **Zacks Recommendation:** **Neutral**
(Since: 08/02/21)
Prior Recommendation: Underperform

Short Term: 1-3 Months | **Zacks Rank:** (1-5) **3-Hold**
Zacks Style Scores: **VGM: C**
Value: C | Growth: D | Momentum: A

Summary

Abbott's strong pipeline continues to open up new opportunities, supporting its 2025 outlook. The Medical Devices arm remains a key growth driver, led by the FreeStyle Libre CGM franchise, including the upcoming dual-analyte sensor integrating glucose and ketone monitoring. In Diagnostics, Abbott's Alinity platforms and Point of Care tests are driving growth outside China, even as VBP-related pricing and volume pressures continue to create a drag. Abbott remains optimistic about its biosimilar strategy, which is expected to boost EPD sales. Within Nutrition, Abbott gains traction, driven by a strong Adult Nutrition and innovation across Ensure and Glucerna brands. Yet, persistent challenges in the Diagnostics, along with tariff impacts, FX fluctuations, and macroeconomic headwinds, continue to weigh modestly on overall growth.

Data Overview

52 Week High-Low	\$141.23 - \$110.86
20 Day Average Volume (sh)	6,816,809
Market Cap	\$223.5 B
YTD Price Change	13.6%
Beta	0.68
Dividend / Div Yld	\$2.36 / 1.8%
Industry	Medical - Products
Zacks Industry Rank	Bottom 31% (166 out of 243)

Last EPS Surprise	0.0%
Last Sales Surprise	-0.2%
EPS F1 Est- 4 week change	0.0%
Expected Report Date	01/28/2026
Earnings ESP	0.8%

P/E TTM	25.8
P/E F1	29.0
PEG F1	2.8
P/S TTM	5.1

Price, Consensus & Surprise⁽¹⁾



Sales and EPS Growth Rates (Y/Y %)⁽¹⁾



Sales Estimates (millions of \$)⁽¹⁾

	Q1	Q2	Q3	Q4	Annual*
2026	11,187 E	11,956 E	12,217 E		48,065 E
2025	10,358 A	11,142 A	11,369 A	11,794 E	44,603 E
2024	9,964 A	10,377 A	10,635 A	10,974 A	41,950 A

EPS Estimates⁽¹⁾

	Q1	Q2	Q3	Q4	Annual*
2026	1.19 E	1.38 E	1.45 E		5.67 E
2025	1.09 A	1.26 A	1.30 A	1.50 E	5.15 E
2024	0.98 A	1.14 A	1.21 A	1.34 A	4.67 A

*Quarterly figures may not add up to annual.

(1) The data in the charts and tables, including the Zacks Consensus EPS and sales estimates, is as of 11/26/2025.

(2) The report's text and the price target are as of 11/18/2025.

Overview

Abbott Park, IL-based Abbott discovers, develops, manufactures and sells a diversified line of healthcare products.

Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Medical Devices.

Its **Established Pharmaceuticals** Division (EPD) includes the branded generics business in emerging markets. The division accounted for 12.6% of total sales in 2024 and registered organic growth of 12.4% from 2023.


Medical Devices includes the diabetes care, vision care and vascular businesses. The segment accounted for 45.3% of total sales in 2024 and reported an 13.4% rise in organic growth from the year-ago number.

Diagnostics manufactures and markets diagnostic systems and tests in four business lines — core laboratory, molecular, point of care and rapid diagnostics. The division accounted for 22.3% of total sales in 2024, marking 3.9% organic decline from 2023.

Nutrition includes a broad line of pediatric and adult nutritional products. The division accounted for 20% of total sales in 2024 and registered 6.4% organic sales growth from the year-ago period.

Abbott has been actively pursuing acquisitions to expand and diversify its portfolio. In April 2023, Abbott acquired Cardiovascular Systems. In September 2021, Abbott acquired Walk Vascular. In October 2017, the company acquired Alere Inc., which was preceded by the acquisition of St. Jude Medical in January 2017.

However, Abbott sold its developed markets branded generics pharmaceuticals business in February 2015 for 110 million shares of Mylan N.V. Abbott retained the branded generics pharmaceuticals business in emerging markets.



Reasons To Buy:

▲ **Strong Prospects Within Core Diagnostics:** Abbott continues to expand its Diagnostics business foothold (consisting of nearly 20% of total revenues in the third quarter of 2025). Over the past few quarters, the company has witnessed increased global demand for routine diagnostic testing (excluding COVID-19 test sales). The company is particularly gaining from strong adoption of its portfolio of respiratory disease tests used to help diagnose influenza, strep throat and respiratory syncytial virus (RSV). Abbott is witnessing adoption of these platforms under a variety of settings, including hospitals, laboratories, urgent care centers, physician offices, retail pharmacies and blood screening facilities. According to Abbott, durable underlying demand across global markets continues to support the company's long-term growth outlook.

Abbott's diversified business portfolio is well-positioned to drive continued momentum in 2025. Accelerated investments in the R&D pipeline are yielding positive results.

Notably, Core Laboratory Diagnostics, excluding China, grew 7% in the third quarter, reflecting robust performance in markets such as the U.S., which showed an acceleration in growth compared to the first half of the year. While the segment continues to face temporary headwinds from volume-based procurement (VBP) pricing dynamics in China, Abbott remains confident in the long-term fundamentals of its Core Lab business. Organic growth of 7.8% in Point of Care Diagnostics was driven by increasing adoption of Abbott's first-of-its-kind concussion test and high-sensitivity troponin test for earlier and more accurate detection of heart attacks, reinforcing the resilience of the broader Diagnostics franchise.

Looking forward, Abbott's continued investments in manufacturing and R&D infrastructure aim to expand its U.S. diagnostics capabilities. Moreover, the upcoming launch of the new Alinity m diagnostic system is expected to strengthen the company's presence in molecular testing, representing a significant future growth opportunity.

▲ **EPD Set for Sustainable Growth:** Abbott's EPD operates solely in emerging geographies, with leading positions in many of the largest and fastest-growing pharmaceutical markets for branded generics in the world. These markets include India, China and countries across Asia, Latin America and the Middle East. Banking on the successful execution of its Branded Generic operating model, EPD is well-positioned for sustained growth in many of these expanding pharmaceutical markets. Focusing on the therapies most needed in faster-growing markets, Abbott continues to sustain its long track record of delivering strong growth, which includes a five-year CAGR for EPD of 8% (as per several market analysts).

According to Abbott, its unique branded generics model was built to focus specifically on key emerging countries where long-term growth in medicines is supported by favorable demographic trends, including higher birth rates, growing middle classes, aging populations with a related rise in chronic diseases and increasing access to healthcare.

Abbott's EPD sales in the third quarter of 2025 increased 7%, led by double-digit growth in its key 15 markets, highlighting broad-based demand and strong commercial execution. From a product portfolio perspective, several therapeutic areas delivered strong contributions, including gastroenterology, cardiometabolic and pain management, which continue to benefit from favorable demographic trends and growing demand for high-quality, affordable medicines. Abbott also continues to make good progress in advancing its biosimilar strategy, a key growth pillar for EPD. During the quarter, the company advanced the regulatory approval process for several biosimilars and remains on track with its planned cadence of product and geographic launches that began this year.

▲ **Sales Recovery Within Nutrition:** Abbott's Nutrition business continues to demonstrate steady growth and market share gains. Despite some ongoing softness in select international pediatric markets, overall Nutrition sales expanded in the third quarter, supported by 4% growth, led by a strong performance in Adult Nutrition.

The company's Ensure brand remains as the primary revenue-generating component of its Adult Nutrition portfolio, with millions of consumers. Strong brand recognition, combined with favorable demographic and dietary trends such as increasing focus on protein intake and immune system health, continues to fuel demand. Growth in Adult Nutrition was driven by 10% growth in international markets, where Abbott continues to see robust demand for both Ensure and Glucerna, its leading brands that support complete and balanced nutrition and help manage dietary requirements for people with diabetes.

To sustain this momentum, Abbott is continuing to invest in product innovation, including the recent launch of a new version of Glucerna containing only 1 gram of sugar and the upcoming launch of a new version of Ensure with 42 grams of protein. Within Pediatric Nutrition, Abbott continues to perform well in the United States, where the Similac brand remains a trusted choice for parents.

▲ **Libre Drives Diabetes Care:** Abbott's Diabetes Care business continued to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring (CGM) system, FreeStyle Libre. In a relatively short span, FreeStyle Libre has achieved global leadership among continuous glucose monitoring systems for both Type 1 and Type 2 users.

The business maintained strong momentum in the third quarter of 2025, with sales of continuous glucose monitors reaching \$2 billion, up 17% year over year. Growth remained robust in both the United States and international markets, reflecting sustained demand and market share gains. The U.S. business grew 19% in the quarter and is up 25% year-to-date, supported by strong uptake of Libre 3 and the continued expansion of coverage and reimbursement.

Abbott is further strengthening its leadership position through ongoing product innovation. The company recently launched new manufacturing capacity to meet rising demand and remains on track for the upcoming launch of its dual-analyte sensor, which integrates glucose and ketone monitoring to help prevent diabetic ketoacidosis. This next-generation device is expected to be a key differentiator in the CGM space and drive further growth, particularly among intensive insulin users.

Earlier in 2024, Abbott also received FDA clearance for two over-the-counter CGM systems, Lingo and Libre Rio, based on Libre technology now used by more than 6 million people worldwide. The expansion into the consumer wellness and Type 2 diabetes markets marks the beginning of a new era for Abbott in the United States.

Reasons To Sell:

- ▼ **Challenges with Diagnostics Business:** Diagnostics Business Drag: Abbott's Diagnostics segment remained a relative drag on overall performance in the third quarter, reflecting persistent headwinds from China's volume-based procurement (VBP) pricing pressures that continue to weigh on both price and volume in its Core Laboratory business. Excluding COVID testing sales, segment growth was modest, as demand softness in China offset otherwise solid performance elsewhere. Core Lab Diagnostics grew outside China, led by strength in the U.S. and other developed markets, but this was not enough to fully counteract the drag from Asia. While Point of Care Diagnostics grew, the broader Diagnostics portfolio remains challenged by market and pricing dynamics. The company expects these pressures to ease gradually, but in the near term, Diagnostics is likely to remain the weakest link in Abbott's growth profile.
- ▼ **Choppy Macro Environment to Weigh on Margins:** The challenging macroeconomic backdrop, including ongoing geopolitical complexities and trade tensions in key markets where Abbott operates, continues to exert pressure on costs. Higher-than-expected increases in expenses such as tariffs, raw materials, and logistics are weighing on margins. These factors could also contribute to broader economic uncertainty, affecting business sentiment in the coming quarters. Industrywide, inflationary trends and supply chain costs remain headwinds for MedTech peers, constraining margin expansion despite steady demand. In the third quarter of 2025, Abbott's adjusted SG&A expenses increased year over year and represented 26.4% of sales. The gross margin contracted 46 basis points to 55.4% and the adjusted operating margin declined 11 basis points to 21.8%, reflecting sustained cost pressures amid an uneven macro environment.
- ▼ **Near-term Weaknesses in China:** Abbott, while continuing to expand its Nutrition business in emerging markets, is still facing softness in Greater China due to challenging market dynamics. In Nutrition, particularly in Pediatric Nutrition, the company has previously taken steps to exit the China market following new food safety regulations and oversupply conditions. The withdrawal from this market, which once represented a meaningful share of Abbott's pediatric nutrition sales, continues to weigh on overall Nutrition performance. In Diagnostics, the Chinese government's VBP policies, intended to lower healthcare costs, remain a significant headwind, pressuring both pricing and volume in Core Lab Diagnostics. As reiterated during the third quarter of 2025, VBP and related dynamics are contributing to a more than \$1 billion headwind for Abbott's Diagnostics business this year, underscoring the ongoing challenges in China.
- ▼ **Foreign Exchange Translation Impacts Sales:** Foreign exchange is a major headwind for Abbott due to a considerable percentage of its revenues coming from outside the United States. The strengthening of the euro and some other developed market currencies has constantly been hampering the company's performance in the international markets. In the third quarter of 2025, foreign exchange had a favorable year-over-year impact of 1.4% on sales, though management noted this was less favorable than previously forecasted. Despite some improvement versus earlier quarters, currency fluctuations remain a source of variability, particularly given the company's large presence in emerging markets. Over the first nine months of 2025, foreign exchange effects have continued to temper reported growth, underscoring ongoing exposure to global currency movements.

The international business environment continues to be challenging globally. The declining demand for the company's COVID-19 tests may limit the overall growth.

Last Earnings Report

Abbott Reports Q3 Earnings Meet and Sales Miss

Abbott reported third-quarter 2025 adjusted earnings per share of \$1.30, which came in line with the Zacks Consensus Estimate. The figure improved 7.4% from the prior-year quarter's level.

GAAP earnings per share was 94 cents, the same as last year's comparable figure.

Q3 Revenues

Worldwide sales of \$11.37 billion were up 6.9% year over year on a reported basis. The top line missed the Zacks Consensus Estimate by 0.24%.

Organically, sales improved 5.5% year over year. Organic sales, ex-COVID, rose 7.5% year over year.

Following the earnings announcement, ABT stock rose 1.4% in pre-market trading today.

Segmental Results in Detail

Abbott operates through four segments — Established Pharmaceuticals, Medical Devices, Nutrition and Diagnostics.

Established Pharmaceuticals' product sales increased 7.5% on a reported basis (7.1% on an organic basis) to \$1.51 billion.

Organic sales in key emerging markets improved 11.1% year over year. This was led by double-digit growth in several countries, including Asia, Latin America and the Middle East.

In the third quarter, the **Medical Devices** segment's sales rose 14.8% year over year on a reported basis (12.5% organically) to \$5.45 billion.

Sales growth was led by double-digit growth in Diabetes Care, Electrophysiology, Rhythm Management, Heart Failure and Structural Heart.

The Diabetes Care division reported organic sales growth of 16.2% year over year, led by sales of continuous glucose monitors, which accounted for \$2.0 billion of total sales.

Structural Heart sales rose 11.3%, and Heart Failure sales improved 12.1% year over year organically.

The Vascular division recorded organic sales growth of 4.7%. The Electrophysiology, Rhythm Management and Neuromodulation divisions recorded organic growth of 13.7%, 13% and 6.8%, respectively, in the quarter under review.

For the third quarter, **Nutrition** sales rose 4.2% year over year on a reported basis (up 4% organically) to \$2.15 billion.

Pediatric Nutrition sales were up 2.4%, and Adult Nutrition sales improved 5.4% organically. According to the company, Adult Nutrition sales benefited from the strong global growth of its market-leading brands, Ensure and Glucerna.

For the third quarter, **Diagnostics** sales declined 6.6% year over year on a reported basis (down 7.8% organically) to \$2.25 billion. Organic sales, ex-COVID, rose 0.4%.

Core Laboratory Diagnostics sales were up 2.2% organically. Molecular Diagnostics sales increased 0.8% on an organic basis. Rapid Diagnostics sales were down 27.7%. Point of Care Diagnostics sales increased 7.8%.

Margin Details

In the third quarter, the gross profit rose 6% year over year to \$6.29 billion despite an 8% increase in the cost of products sold (excluding amortization expense). However, the gross margin contracted 46 basis points (bps) to 55.4%.

Selling, general and administration expenses rose 5.4% year over year to \$3.05 billion. Research and development expenses rose 7.4% year over year to \$766 million. The company reported an adjusted operating profit of \$2.48 billion, up 6.4% year over year. The adjusted operating margin contracted 11 bps to 21.8%.

2025 Financial Guidance

For the full year, Abbott expects adjusted diluted earnings per share to be in the range of \$5.12 -\$5.18 (earlier \$5.10-\$5.20). The Zacks Consensus Estimate for the metric is pegged at \$5.15.

Full-year organic sales growth, excluding COVID-19 testing-related sales, is expected to be in the range of 7.5-8.0% (same as earlier). When including COVID-19 testing-related sales, organic sales growth is forecasted to be 6-7% (unchanged). The Zacks Consensus Estimate for Abbott's sales is currently pegged at \$44.66 billion.

FY Quarter Ending **12/31/2024**

Earnings Reporting Date	Oct 15, 2025
Sales Surprise	-0.23%
EPS Surprise	0.00%
Quarterly EPS	1.30
Annual EPS (TTM)	4.99

Recent News

Abbott's Navitor TAVI System Receives CE Mark: Aug. 29, 2025

Abbott announced it has received CE Mark in Europe for an expanded indication for the company's Navitor transcatheter aortic valve implantation (TAVI) system to treat people with symptomatic, severe aortic stenosis who are at low or intermediate risk for open-heart surgery.

Abbott's Dissolving Stent Receives CE Mark: Aug. 25, 2025

Abbott announced it has received CE Mark in Europe for the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with peripheral artery disease (PAD) below the knee (BTK).

Valuation

Abbott shares are up 14.9% year to date and up 11.1% in the trailing 12-months. Stocks in the Zacks sub-industry are up 3.5% while the Zacks Medical sector is up 4.6% in the year-to-date period. Over the past year, the Zacks sub-industry is down 1.3% and sector is up 0.1%.

The S&P 500 index is up 16% in the in the year-to-date period and up 15.7% in the past year.

The stock is currently trading at 23.2X Forward 12-months earnings, which compares to 20.4X for the Zacks sub-industry, 20.6X for the Zacks sector and 23.2X for the S&P 500 index.

Over the past five years, the stock has traded as high as 30.3X and as low as 19.8X, with a 5-year median of 23.8X. Our Neutral recommendation indicates that the stock will perform in line with the market. Our \$138 price target reflects 24.6X forward 12-months earnings.


The table below shows summary valuation data for ABT.

Valuation Multiples - ABT					
		Stock	Sub-Industry	Sector	S&P 500
P/E F 12M	Current	23.19	20.39	20.55	23.20
	5-Year High	30.31	27.44	23.63	23.81
	5-Year Low	19.81	17.80	17.88	15.73
	5-Year Median	23.84	21.97	20.59	21.20
P/S F12M	Current	4.74	3.00	2.11	5.29
	5-Year High	6.32	4.41	3.39	5.52
	5-Year Low	3.80	2.54	2.01	3.84
	5-Year Median	4.77	3.19	2.63	5.06
P/B TTM	Current	4.41	2.89	3.72	8.33
	5-Year High	7.22	4.43	6.04	9.19
	5-Year Low	4.02	2.42	3.46	6.62
	5-Year Median	5.04	3.12	4.52	8.05

As of 11/17/2025

Source: Zacks Investment Research

Industry Analysis⁽¹⁾ Zacks Industry Rank: Bottom 31% (166 out of 243)



Top Peers⁽¹⁾

Company (Ticker)	Rec	Rank
Boston Scientific Co...(BSX)	Neutral	3
EssilorLuxottica Uns...(ESLOY)	Neutral	3
Medtronic PLC (MDT)	Neutral	3
Koninklijke Philips ...(PHG)	Neutral	3
Stryker Corporation (SYK)	Neutral	3
Zimmer Biomet Holdin...(ZBH)	Neutral	3
Baxter International...(BAX)	Underperform	3
Owens & Minor, Inc. (OMI)	Underperform	4

Industry Comparison⁽¹⁾ Industry: Medical - Products

	ABT	X Industry	S&P 500	ESLOY	MDT	SYK
Zacks Recommendation (Long Term)	Neutral	-	-	Neutral	Neutral	Neutral
Zacks Rank (Short Term)	3	-	-	3	3	3
VGM Score	C	-	-	C	D	B
Market Cap	223.51 B	0.00 M	37.87 B	168.18 B	134.64 B	142.37 B
# of Analysts	10		22	2	11	10
Dividend Yield	1.84%	%	1.49%	0.89%	2.70%	0.90%
Value Score	C	-	-	C	C	C
Cash/Price	0.03	NA	0.04	0.02	0.06	0.02
EV/EBITDA	21.07	NA	14.46	NA	16.73	33.88
PEG Ratio	2.84	NA	2.20	4.09	2.77	2.64
Price/Book (P/B)	4.36	NA	3.32	3.86	2.76	6.54
Price/Cash Flow (P/CF)	19.53	NA	14.79	24.68	13.55	24.68
P/E (F1)	28.95	NA	20.09	44.07	18.60	27.47
Price/Sales (P/S)	5.10	NA	3.03	NA	3.87	5.84
Earnings Yield	4.01%	NA%	4.96%	2.27%	5.38%	3.64%
Debt/Equity	0.23	NA	0.57	0.18	0.57	0.68
Cash Flow (\$/share)	6.58	NA	8.99	7.36	7.75	15.08
Growth Score	D	-	-	C	F	C
Hist. EPS Growth (3-5 yrs)	-0.52%	NA%	8.17%	NA	3.56%	11.21%
Proj. EPS Growth (F1/F0)	-4.93%	NA%	8.30%	11.96%	2.91%	11.16%
Curr. Cash Flow Growth	3.38%	NA%	7.10%	5.09%	3.92%	12.88%
Hist. Cash Flow Growth (3-5 yrs)	5.29%	NA%	7.32%	8.16%	2.31%	7.98%
Current Ratio	1.70	NA	1.18	0.97	2.42	1.85
Debt/Capital	18.45%	NA%	38.16%	15.06%	36.17%	40.53%
Net Margin	31.88%	NA%	12.77%	NA	13.71%	12.07%
Return on Equity	17.60%	NA%	17.03%	NA	14.86%	24.07%
Sales/Assets	0.53	NA	0.53	NA	0.38	0.53
Proj. Sales Growth (F1/F0)	-4.80%	%	5.59%	13.50%	7.50%	11.00%
Momentum Score	A	-	-	B	B	A
Daily Price Chg	0.38%	NA%	0.91%	1.31%	-0.31%	-0.74%
1 Week Price Chg	-1.90%	NA%	2.24%	-4.03%	5.56%	1.67%
4 Week Price Chg	3.30%	NA%	-1.81%	-1.59%	14.49%	0.73%
12 Week Price Chg	-2.75%	NA%	5.46%	20.58%	13.84%	-4.19%
52 Week Price Chg	8.06%	NA%	12.36%	49.33%	21.73%	-4.08%
20 Day Average Volume	6,816,809	0	3,102,844	49,360	8,319,191	1,924,135
(F1) EPS Est 1 week change	0.02%	NA%	0.00%	-0.48%	0.00%	0.00%
(F1) EPS Est 4 week change	0.00%	NA%	0.26%	-0.48%	0.56%	0.42%
(F1) EPS Est 12 week change	0.02%	NA%	0.60%	1.81%	0.54%	0.39%
(Q1) EPS Est Mthly Chg	0.00%	NA%	-0.11%	NA	-0.86%	-0.04%

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	C
Growth Score	D
Momentum Score	A
VGM Score	C

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless otherwise indicated in the report's first-page footnote. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.